Pfizer Inc on Tuesday forecast a bigger-than-expected drop in sales of its COVID-19 vaccine and treatment for 2023, intensifying investor concerns over demand for the products as governments cut orders and work through inventories. Chief Executive Albert Bourla said that 2023 should be a "transition year" for Pfizer’s COVID products, before potentially returning to growth in 2024.
About the Author
